www.bhdu.cn-夜肉伦伦影院无码 ,国产精品www夜色视频,3d动漫精品啪啪一区二区免费,久久婷婷综合缴情亚洲狠狠

<blockquote id="4uc0g"><tfoot id="4uc0g"></tfoot></blockquote>
  • <fieldset id="4uc0g"><table id="4uc0g"></table></fieldset>
  • <fieldset id="4uc0g"><menu id="4uc0g"></menu></fieldset>
  • <ul id="4uc0g"><sup id="4uc0g"></sup></ul>
    <strike id="4uc0g"></strike>
    <del id="4uc0g"></del>
    <strike id="4uc0g"></strike>
    更新于 1月2日

    Associate Director, in vivo Pharmacology (MJ017086)

    3萬-6萬
    • 上海浦東新區(qū)
    • 經(jīng)驗(yàn)不限
    • 學(xué)歷不限
    • 全職
    • 招1人

    職位描述

    生物藥新藥藥理研究

    The Head of Comparative Medicine at Shanghai site is a critical leadership role responsible for managing and directing the preclinical research and development activities focused on autoimmune disease and oncology therapeutics. This position requires a deep understanding of comparative medicine and the ability to align local site activities with the broader strategic goals of the company.

    Responsibilities

    Site Management:

    • Oversee the day-to-day operations of the comparative medicine site, ensuring alignment with corporate objectives and standards.
    • Manage a team of scientists and researchers, providing direction, mentorship, and support for their professional development.
    • Oversee the budget and resource allocation for the team to ensure efficient operations.

    Research and Development:

    • Lead the site’s efforts in developing and implementing preclinical models and assays to evaluate the efficacy and safety of new drug candidates for autoimmune and oncology diseases.
    • Collaborate with cross-functional teams to translate research findings into clinical development plans.
    • Collaborate with the Beijing Comparative Medicine team to ensure consistency and integration of research efforts across sites.
    • Stay abreast of the latest scientific advancements in autoimmune and oncology disease research

    Collaboration and Communication:

    • Maintain regular communication with the Head of Comparative Medicine to align strategies and share updates.
    • Represent the site at internal meetings, conferences, and events to ensure effective communication and collaboration.


    Qualifications:

    Education: Ph.D. or equivalent in Comparative Medicine, Immunology, Biology, or a related field. Experience: A minimum of 6 years of experience in industry preclinical research, with a focus on autoimmune or oncology diseases. Expertise: A successful track record of contributing to the advancement of drug candidates from preclinical to clinical stages. Leadership: Proven track record of leading research teams and managing research projects. Communication: Strong communication skills, with the ability to effectively liaise with a central team and present complex scientific information.



    百濟(jì)神州全球勝任力
    當(dāng)我們通過以下十二項(xiàng)全球勝任力,展現(xiàn)出 "患者為先"、"無界協(xié)作"、"銳意創(chuàng)新 "和 "追求卓越 "的價(jià)值觀時(shí),我們就能幫助全世界更多患者獲得更多負(fù)擔(dān)得起的藥品。
    ●團(tuán)隊(duì)協(xié)作
    ●提供并征求坦誠及可行的反饋
    ●自我認(rèn)知
    ●兼容并蓄
    ●積極主動
    ●開拓精神
    ●持續(xù)學(xué)習(xí)
    ●擁抱變化
    ●結(jié)果導(dǎo)向
    ●分析性思維/數(shù)據(jù)分析
    ●卓越財(cái)務(wù)
    ●清晰溝通
    BeiGene Global Competencies
    When we exhibit our values of Patients First, Collaborative Spirit, Bold Ingenuity and Driving Excellence, through our twelve global competencies below, we help get more affordable medicines to more patients around the world.
    ●Fosters Teamwork
    ●Provides and Solicits Honest and Actionable Feedback
    ●Self-Awareness
    ●Acts Inclusively
    ●Demonstrates Initiative
    ●Entrepreneurial Mindset
    ●Continuous Learning
    ●Embraces Change
    ●Results-Oriented
    ●Analytical Thinking/Data Analysis
    ●Financial Excellence
    ●Communicates with Clarity
    求職者隱私申明:
    百濟(jì)神州致力于尊重和保護(hù)您的個(gè)人信息權(quán)利,并承諾依據(jù)合法、正當(dāng)、必要和誠信的原則處理您的個(gè)人信息(包括個(gè)人敏感信息 )。
    由于百濟(jì)神州在全球范圍內(nèi)開展業(yè)務(wù),我們可能需要基于人力資源管理等合理業(yè)務(wù)目的而將您的個(gè)人信息發(fā)送和/或存儲在位于您所在國家以外其他國家(例如:美國)的服務(wù)器和數(shù)據(jù)庫中,詳情參見百濟(jì)神州《求職者隱私政策》(百濟(jì)神州官網(wǎng) - 隱私政策 - 求職者隱私政策)。
    如您主動向我們提供您的簡歷信息或其他個(gè)人信息,則視為您已經(jīng)充分理解并確認(rèn)接受百濟(jì)神州《求職者隱私政策》內(nèi)容。如您對此有任何疑問的,請勿提交簡歷信息或其他個(gè)人信息。
    BeiGene is committed to respect and protect your personal information rights, and will process your personal information, including your sensitive personal information, based on the principles of legality, legitimacy, necessity, and integrity.
    Due to the reasonable business need for human resource management as a result of BeiGene’s global operation, your personal information may be transferred and/ or stored in a server/database located in a third country (e.g., the United States) other than your own country. For further details, please refer to BeiGene Job Applicant Privacy Policy (BeiGene official website - Privacy Policy - Job Applicant Privacy Policy).
    If you voluntarily provide your resume or other personal information to us, it is deemed as you have thoroughly acknowledged and accepted BeiGene Job Applicant Privacy Policy. If you have any concern, please DO NOT submit your resume or any other personal information.

    工作地點(diǎn)

    百濟(jì)神州(上海)醫(yī)藥研發(fā)有限公司

    職位發(fā)布者

    張婧媛/人事經(jīng)理

    今日活躍
    立即溝通
    公司Logo百濟(jì)神州北京公司標(biāo)簽
    About BeiGene BeiGene is a publically traded(BGNE, NASDAQ), globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. Our cancer biology platform addresses the importance of tumor-immune system interactions and the value of primary tumor biopsies in developing new cancer models. We have a global team of over 200 individuals, including over 150 scientists and clinicians, and a world-renowned scientific advisory board, with deep scientific talent, extensive pharmaceutical experience, and a commitment to improving the lives of cancer patients around the world. Our clinical pipeline is comprised of novel oral small molecules and monoclonal antibodies(mAb) for cancer, including an anti-PD-1 monoclonal antibody, a best-in-class BTK inhibitor, a RAF dimer inhibitor, a best-in-class PARP inhibitor, and a variety of combination clinical studies. In addition, our robust preclinical programs are expected to generate more small molecule and mAb drugs for clinical development in coming years. For more information, please visit our website at www.beigene.com.
    公司主頁
    国产毛片一区二区三区视频| 日韩在线一区二区三区观看| 大地资源在线观看中文免费| gogogo高清在线观看| 亚洲成a人片在线观看中文| 国产另类ts人妖一区二区| 国产精品一区二区在线观看| 亚洲国产日韩精品一区二区| 成全视频免费高清游戏| 久久久WWW成人免费精品|